MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Author(s)
Tostanoski, Lisa H.; Wegmann, Frank; Martinot, Amanda J.; Loos, Carolin; McMahan, Katherine; Mercado, Noe B.; Yu, Jingyou; Chan, Chi N.; Bondoc, Stephen; Starke, Carly E.; Nekorchuk, Michael; Busman-Sahay, Kathleen; Piedra-Mora, Cesar; Wrijil, Linda M.; Ducat, Sarah; Custers, Jerome; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Lin, Zijin; Mahrokhian, Shant H.; Nampanya, Felix; Nityanandam, Ramya; Pessaint, Laurent; Porto, Maciel; Ali, Vaneesha; Benetiene, Dalia; Tevi, Komlan; Andersen, Hanne; Lewis, Mark G.; Schmidt, Aaron G.; Lauffenburger, Douglas A; Alter, Galit; Estes, Jacob D.; Schuitemaker, Hanneke; Zahn, Roland; Barouch, Dan H.; ... Show more Show less
Thumbnail
Downloads41591-020-1070-6.pdf (8.338Mb)
Publisher with Creative Commons License

Publisher with Creative Commons License

Creative Commons Attribution

Terms of use
Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/
Metadata
Show full item record
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters and nonhuman primates have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
Date issued
2020-09
URI
https://hdl.handle.net/1721.1/127202
Department
Massachusetts Institute of Technology. Department of Biological Engineering
Journal
Nature Medicine
Citation
Tostanoski, Lisa H. et al. "Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters." Nature Medicine (September 2020): doi.org/10.1038/s41591-020-1070-6 © 2020 Springer Nature
Version: Final published version

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.